Prevencio Presents AI-Driven Platform for Medical Diagnostic Test Development

Prevencio, Inc. (Kirkland, WA, USA) is showcasing its leading-edge, artificial intelligence (AI)-powered HART platform and blood tests at AACC 2023.

Prevencio has announced the culminative presentation of patient data demonstrating that its AI-empowered HART blood tests exhibit high accuracy across a diverse patient demographic, including those affected by diabetes, chronic kidney disease, hypertension, obesity, coronary heart disease, heart failure, chronic total occlusion (CTO) of the heart arteries, and Kawasaki disease. The HART platform is disease agnostic, thereby allowing the development of diagnostics that extend beyond cardiac diseases. Presently, Prevencio's two primary tests, HART CVE and HART CADhs, are accessible to medical professionals for patient use. HART CVE calculates a patient's one-year risk for a heart attack, stroke, or cardiovascular death, whereas HART CADhs evaluates if a patient has a blockage in the heart arteries, indicating an imminent risk of a heart attack. Researchers from Massachusetts General Hospital (MGH, Boston, MA, USA) tested more than 1,250 patients undergoing coronary or peripheral angiography to collaborate in the development and validation of the AI-driven HART platform which has produced seven highly accurate, algorithmic multiple protein blood tests.

“It is impressive the HART tests provide robust accuracy amongst a wide range of patients,” said James L. Januzzi, MD, a practicing cardiologist at MGH, and principal investigator in development, validation, and ongoing testing of six of the seven HART tests. “With the rapid rise in cardiovascular disease, better tools to recognize risk and intervene proactively are needed. Our data suggest that AI-derived, multi-protein, algorithmically scored blood tests may be useful to individualize cardiac risk assessment and foster aggressive primary and secondary cardiovascular prevention. We are especially excited with our most recent data demonstrating the accuracy of HART CVE in assessing risk in patients with total chronic occlusion of the coronary arteries and look forward to using the HART platform to develop additional clinical applications and diagnostic tests.”

Related Links:
Prevencio, Inc.
MGH 

Visit expo >

New

Gold Member

Strep Pneumoniae Rapid Test

Strep Pneumoniae (6503 – 6573)

Gold Member

TORCH Panel Rapid Test

Rapid TORCH Panel Test

New

Centrifuge

Mikro 200

New

Vaginal pH Screening Kit

Vaginal pH Screening Kit